2017
Balloon-Assisted Transarterial Chemoembolization: A Nascent Strategy for the Treatment of Hepatocellular Carcinoma
Kishore S, Cheng W, Smirniotopoulos J, Madoff D. Balloon-Assisted Transarterial Chemoembolization: A Nascent Strategy for the Treatment of Hepatocellular Carcinoma. Digestive Disease Interventions 2017, 01: 115-120. DOI: 10.1055/s-0037-1603961.Peer-Reviewed Original ResearchTransarterial chemoembolizationHepatocellular carcinomaLiver-confined hepatocellular carcinomaTreatment of HCCMajority of patientsBalloon catheter systemCancer-related mortalityLow-profile cathetersConventional transarterial chemoembolizationConventional TACECurative optionTransarterial therapiesLeading causeTherapeutic strategiesMicrocatheter technologyIntratumoral administrationChemotherapeutic agentsPatientsChemoembolizationCarcinomaTreatmentNascent strategyCatheterMajorityTherapy
2007
Hepatic Arterial Embolization and Chemoembolization in the Management of Patients with Large-Volume Liver Metastases
Kamat PP, Gupta S, Ensor JE, Murthy R, Ahrar K, Madoff DC, Wallace MJ, Hicks ME. Hepatic Arterial Embolization and Chemoembolization in the Management of Patients with Large-Volume Liver Metastases. CardioVascular And Interventional Radiology 2007, 31: 299-307. PMID: 17922160, DOI: 10.1007/s00270-007-9186-3.Peer-Reviewed Original ResearchConceptsProgression-free survivalHepatic arterial embolizationGastrointestinal stromal tumorsOverall survivalNeuroendocrine tumorsRadiologic responseArterial embolizationDisease stabilizationLiver involvementLiver metastasesMajor complicationsLonger progression-free survivalLiver tumor burdenMedian overall survivalMetastatic neuroendocrine tumorsProcedure-related mortalityMajority of patientsManagement of patientsAdditional risk factorsHigh response rateStable diseaseSymptom palliationPartial responsePerformance statusProgressive disease
2006
Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors
Kobayashi K, Gupta S, Trent JC, Vauthey J, Krishnamurthy S, Ensor J, Ahrar K, Wallace MJ, Madoff DC, Murthy R, McRae SE, Hicks ME. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors. Cancer 2006, 107: 2833-2841. PMID: 17096432, DOI: 10.1002/cncr.22336.Peer-Reviewed Original ResearchConceptsHepatic artery chemoembolizationGastrointestinal stromal tumorsUse of imatinibOverall survivalOS timeLiver diseaseStromal tumorsTumor responseMetastatic gastrointestinal stromal tumorsExtensive liver involvementMedian OS timeObjective tumor responseMedian PFS timeProgression-free survivalKaplan-Meier methodMajority of patientsDurable tumor responsesExtrahepatic diseaseOS ratesRadiologic responseStable diseaseDisease stabilizationPFS timeExtrahepatic metastasesLiver involvementUpdate on the Management of Neuroendocrine Hepatic Metastases
Madoff DC, Gupta S, Ahrar K, Murthy R, Yao JC. Update on the Management of Neuroendocrine Hepatic Metastases. Journal Of Vascular And Interventional Radiology 2006, 17: 1235-1250. PMID: 16923972, DOI: 10.1097/01.rvi.0000232177.57950.71.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBrachytherapyCatheter AblationChemoembolization, TherapeuticClinical Trials as TopicCryosurgeryEthanolHepatectomyHumansLiver NeoplasmsLiver TransplantationNeoplasms, Unknown PrimaryNeuroendocrine TumorsPractice Guidelines as TopicRadiology, InterventionalTomography, X-Ray ComputedTreatment OutcomeConceptsNeuroendocrine tumorsHepatic metastasesLong indolent courseYear of diagnosisMajority of patientsTime of diagnosisCare of patientsUnusual clinical presentationNeuroendocrine hepatic metastasesTumor growth patternMost patientsIndolent courseClinical presentationRespiratory tractPatientsOrgan systemsMetastasisDiagnosisImage-guided interventionsGrowth patternMalignancyTumorsTractCareYttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer
Murthy R, Oh Y, Tam A, Gupta S, Madoff D, Glisson B. Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer. Journal Of Clinical Oncology 2006, 24: 17122-17122. DOI: 10.1200/jco.2006.24.18_suppl.17122.Peer-Reviewed Original ResearchHepatic metastasesSIR-SpheresLung cancerLiver metastasesSystemic therapyAdvanced liver metastasesLiver-dominant metastasesPrimary lung malignancyRegional hepatic therapyUnresectable hepatic metastasesColorectal liver metastasesLocal disease controlMetastatic lung cancerYttrium-90 Microsphere TreatmentMajority of patientsProgression of diseaseGr. 1Dominant metastasesStable diseaseVisceral arteriographyMedian doseSystemic chemotherapyArterial embolizationLine therapyMedian interval